Q3 EPS Estimates for Zimmer Biomet Lowered by Zacks Research

Zimmer Biomet Holdings, Inc. (NYSE:ZBH) – Analysts at Zacks Research lowered their Q3 2025 EPS estimates for Zimmer Biomet in a note issued to investors on Monday, March 10th. Zacks Research analyst R. Department now anticipates that the medical equipment provider will earn $1.93 per share for the quarter, down from their prior estimate of $1.96. The consensus estimate for Zimmer Biomet’s current full-year earnings is $8.22 per share. Zacks Research also issued estimates for Zimmer Biomet’s Q4 2025 earnings at $2.49 EPS.

ZBH has been the subject of several other research reports. Raymond James lowered their target price on shares of Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research note on Friday, February 7th. Stifel Nicolaus increased their target price on shares of Zimmer Biomet from $130.00 to $138.00 and gave the stock a “buy” rating in a research note on Thursday, January 23rd. JPMorgan Chase & Co. raised shares of Zimmer Biomet from a “neutral” rating to an “overweight” rating and raised their price objective for the company from $125.00 to $128.00 in a research note on Tuesday, December 17th. Needham & Company LLC reissued a “hold” rating on shares of Zimmer Biomet in a research note on Friday, February 7th. Finally, JMP Securities reissued a “market outperform” rating and issued a $140.00 price objective on shares of Zimmer Biomet in a research note on Friday, February 7th. Two equities research analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have issued a buy rating to the company’s stock. Based on data from MarketBeat, the company presently has a consensus rating of “Hold” and an average target price of $124.15.

Zimmer Biomet Trading Down 3.0 %

Shares of ZBH stock opened at $104.10 on Wednesday. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.91 and a quick ratio of 0.99. The firm has a market cap of $20.72 billion, a PE ratio of 23.39, a price-to-earnings-growth ratio of 1.95 and a beta of 1.04. The company has a 50-day moving average of $105.65 and a two-hundred day moving average of $107.05. Zimmer Biomet has a 1-year low of $97.69 and a 1-year high of $133.90.

Zimmer Biomet (NYSE:ZBH) last announced its quarterly earnings data on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $2.30 by $0.01. Zimmer Biomet had a net margin of 11.77% and a return on equity of 12.99%. During the same period last year, the company earned $2.20 earnings per share.

Zimmer Biomet Announces Dividend

The firm also recently announced a quarterly dividend, which will be paid on Wednesday, April 30th. Stockholders of record on Monday, March 31st will be given a dividend of $0.24 per share. The ex-dividend date of this dividend is Monday, March 31st. This represents a $0.96 dividend on an annualized basis and a dividend yield of 0.92%. Zimmer Biomet’s dividend payout ratio (DPR) is presently 21.57%.

Insider Transactions at Zimmer Biomet

In related news, SVP Lori Winkler sold 1,443 shares of Zimmer Biomet stock in a transaction on Wednesday, March 5th. The shares were sold at an average price of $104.40, for a total value of $150,649.20. Following the transaction, the senior vice president now directly owns 8,768 shares in the company, valued at $915,379.20. This trade represents a 14.13 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Insiders own 0.95% of the company’s stock.

Hedge Funds Weigh In On Zimmer Biomet

A number of hedge funds and other institutional investors have recently bought and sold shares of the company. Dodge & Cox grew its position in Zimmer Biomet by 12.0% in the 4th quarter. Dodge & Cox now owns 19,118,436 shares of the medical equipment provider’s stock valued at $2,019,480,000 after buying an additional 2,044,645 shares during the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Zimmer Biomet by 1.2% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 14,760,444 shares of the medical equipment provider’s stock worth $1,559,147,000 after purchasing an additional 176,337 shares in the last quarter. Geode Capital Management LLC boosted its position in shares of Zimmer Biomet by 2.6% during the 3rd quarter. Geode Capital Management LLC now owns 4,879,385 shares of the medical equipment provider’s stock worth $524,942,000 after purchasing an additional 125,852 shares in the last quarter. Van ECK Associates Corp boosted its position in shares of Zimmer Biomet by 5.9% during the 4th quarter. Van ECK Associates Corp now owns 3,955,449 shares of the medical equipment provider’s stock worth $417,814,000 after purchasing an additional 218,688 shares in the last quarter. Finally, Franklin Resources Inc. boosted its position in shares of Zimmer Biomet by 398.7% during the 4th quarter. Franklin Resources Inc. now owns 3,497,764 shares of the medical equipment provider’s stock worth $369,469,000 after purchasing an additional 2,796,372 shares in the last quarter. 88.89% of the stock is currently owned by hedge funds and other institutional investors.

About Zimmer Biomet

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.